Novo Nordisk’s diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular ...
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...
Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...
Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...
This makes semaglutide the first drug to show benefits in both cardiovascular outcomes and walking function, Bonaca said.
People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to experience cardiovascular death, heart attack or stroke ...
Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...
News-Medical.Net on MSN2d
Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...
Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...
Biopharma leaders react to the forced resignation of CDER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback